ClinicalTrials.Veeva

Menu
H

Hightower Clinical | Oklahoma City, OK

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Risankizumab
Upadacitinib
ABT-494
Ozanimod
Pembrolizumab
ABX464
Milvexian
Ustekinumab
Eptinezumab
Trastuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 54 total trials

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Met...

Active, not recruiting
Metastasis From Malignant Tumor of Prostate
Drug: 177Lu-PSMA-I&T
Drug: Abiraterone with Prednisone or Enzalutamide

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femor...

Enrolling
Osteoarthritis (OA) of the Knee
Drug: TPX-100 200mg, Once weekly for 4 weeks
Other: PBS

The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PR...

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Rocatinlimab

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Drug: Palbociclib
Drug: Giredestrant

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Active, not recruiting
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-ce...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts A-C)
Drug: Mosunetuzumab (Cohorts D-E)

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 1...

Enrolling
Plaque Psoriasis
Drug: Apremilast

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this stu...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: TAK-788

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-a...

Enrolling
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Drug: Avacopan
Drug: Standard of Care

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Ph...

Enrolling
Locally Advanced or Metastatic Breast Cancer
Drug: LHRH Agonist
Drug: Phesgo

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcuta...

Enrolling
Metastatic Breast Cancer
Drug: Inavolisib
Drug: Optional Endocrine Therapy of Investigator's Choice

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Litifilimab

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered...

Enrolling
Non-small Cell Lung Cancer
Thoracic Tumors
Drug: Carboplatin
Drug: Pemetrexed

Trial sponsors

AbbVie logo
Abbott logo
Amgen logo
Celgene logo
Pfizer logo
Roche logo
A
Gilead Sciences logo
Janssen (J&J Innovative Medicine) logo
Aussie Bubs logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems